Detalhe da pesquisa
1.
Development of methodology for assessing steroid-tapering in clinical trials for biologics in asthma.
Respir Res
; 23(1): 45, 2022 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35246123
2.
From DREAM to REALITI-A and beyond: Mepolizumab for the treatment of eosinophil-driven diseases.
Allergy
; 77(3): 778-797, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34402066
3.
A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma.
Br J Clin Pharmacol
; 88(2): 702-712, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34292606
4.
Evaluating enrollment and outcome criteria in trials of biologics for chronic rhinosinusitis with nasal polyps.
Ann Allergy Asthma Immunol
; 129(2): 160-168, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35398492
5.
Impact of baseline clinical asthma characteristics on the response to mepolizumab: a post hoc meta-analysis of two Phase III trials.
Respir Res
; 22(1): 184, 2021 06 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-34158028
6.
Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial.
J Allergy Clin Immunol
; 146(6): 1397-1405, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-32956756
7.
Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease.
N Engl J Med
; 377(17): 1613-1629, 2017 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-28893134
8.
Pharmacogenetic investigation of efficacy response to mepolizumab in eosinophilic granulomatosis with polyangiitis.
Rheumatol Int
; 40(8): 1301-1307, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32009195
9.
Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype.
J Allergy Clin Immunol
; 144(5): 1336-1342.e7, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31425781
10.
Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma.
J Allergy Clin Immunol
; 143(5): 1742-1751.e7, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30359681
11.
Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis.
J Allergy Clin Immunol
; 143(6): 2170-2177, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-30578883
12.
Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis.
Respir Res
; 20(1): 83, 2019 May 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31053134
13.
Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight/body mass index: meta-analysis of MENSA and MUSCA.
Respir Res
; 20(1): 169, 2019 Jul 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-31362741
14.
Association of depressive symptoms with health status and markers of uncontrolled severe asthma.
Allergy Asthma Proc
; 40(4): 230-239, 2019 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31262378
15.
Biomarkers for severe eosinophilic asthma.
J Allergy Clin Immunol
; 140(6): 1509-1518, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-29221581
16.
Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma.
J Allergy Clin Immunol
; 139(4): 1167-1175.e2, 2017 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-27726946
17.
Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
N Engl J Med
; 371(13): 1189-97, 2014 Sep 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-25199060
18.
Mepolizumab treatment in patients with severe eosinophilic asthma.
N Engl J Med
; 371(13): 1198-207, 2014 Sep 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-25199059
19.
Update: Mepolizumab treatment in patients with severe eosinophilic asthma and prior omalizumab use.
Allergy
; 75(4): 942-946, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31520471
20.
ADRB2 p.Thr164Ile association with hospitalization depends upon asthma severity.
J Allergy Clin Immunol
; 143(5): 1962-1965.e4, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30682460